期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

B7-H6分子在恶性肿瘤中的研究进展 被引量：1

Progress of B7-H6 molecule in malignant tumors
原文传递
导出
摘要 B7-H6分子是近年来发现的新型B7家族成员,可与自然杀伤(NK)细胞活化型受体NKp30特异性结合,介导NK细胞发挥肿瘤免疫杀伤作用。B7-H6在正常细胞表达中缺失,而在多种肿瘤细胞中表达上调。B7-H6分子的内在调控机制逐渐被揭示,B7-H6的靶向治疗在动物实验中获得了较好的效果,应用前景广阔。文章对B7-H6分子在恶性肿瘤中的最新进展进行综述。 B7-H6 has been discovered as a new member of the B7 family in recent years, it can specifically bind to the NKp30, an activated receptor of natural killer (NK) cells to mediate NK cells' tumor immunity killing effect. B7-H6 expression is upregulated in a wide variety of malignant tumor cells, but expression deficiency in normal tissue is detected. The intrinsic mechanism of B7-H6 regulation has been explored, and the treatment targeting B7-H6 has achieved a good effect in animal experiments, which shows a wide prospect of clinical application. This paper summarizes the latest progress of B7-H6 molecule in malignant tumors.
作者 杨思源 王晶 克晓燕 Yang Siyuan;Wang Jing;Ke Xiaoyan(Department of Hematology, Peking University Third Hospital, Beijing 100191, China)
机构地区 北京大学第三医院血液科
出处 《肿瘤研究与临床》 CAS 2019年第4期272-275,共4页 Cancer Research and Clinic
关键词 肿瘤逃逸 肿瘤 杀伤细胞 天然 B7-H6 Tumor escape Neoplasms Killer cells, natural B7-H6
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献34

  • 1Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG-3 potential mechanisms of action[J]. Nat Rev Immunol, 2015, 15(1): 45-56.
  • 2Fourcade J, Sun Z, Pagliano O, et al. CD8(+)T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD1[J]. Cancer Res, 2012, 72(4): 887-896.
  • 3Romo-Tena J, Gómez-Martín D, Alcocer-Varela J, et al. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance[J]. Autoimmun Rev, 2013, 12(12): 1171-1176.
  • 4Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies[J]. Leukemia, 2014, 28(9): 1784-1792.
  • 5Rudolph M, Hebel K, Miyamura Y, et al. Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo[J]. J Immunol, 2011, 186(10): 5580-5589.
  • 6Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti- CTLA-4 antibodies[J]. J Exp Med, 2009, 206(8):1717-1725.
  • 7Pistillo MP, Tazzari PL, Palmisano GL, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells [J]. Blood, 2003, 101(1):202-209.
  • 8Mansour A, Elkhodary T, Darwish A, et al. Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2014, 55(9): 2120-2124.
  • 9Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents[J]. Leukemia, 2014, 28(6):1280-1288.
  • 10Zhong RK, Loken M, Lane TA, et al. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system[J]. Cytotherapy, 2006, 8(1): 3-12.

共引文献7

同被引文献3

引证文献1

二级引证文献1

肿瘤研究与临床
2019年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部